Brooks Laboratories Limited disclosed that its Board of Directors, at a meeting held on June 19, 2026, approved the sale of 51,220 equity shares held in Brooks Steriscience Limited to Steriscience Specialties Private Limited.
The transaction involves a cash consideration of ₹20,760 per share, aggregating to ₹106,33,27,200 (Rupees One Hundred Six Crore Thirty-Three Lakh Twenty-Seven Thousand Two Hundred only). This represents a partial monetization of the company's investment and does not constitute a complete divestment.
Shareholding Impact
- Shares sold: 51,220 equity shares
- Percentage of shareholding disposed: 16.33%
- Pre-transaction holding: 49.00% of paid-up share capital
- Post-transaction holding: 32.67% of paid-up share capital (102,440 equity shares)
- Transaction does not constitute a complete divestment
Transaction Details
- Approval date: June 19, 2026
- Counterparty: Steriscience Specialties Private Limited
- Price per share: ₹20,760
- Total consideration: ₹106,33,27,200
- Not a related party transaction
Use of Proceeds
The proceeds from the transaction will be deployed towards the company's growth strategy, including:
- Expansion of operations
- Capacity enhancement
- Funding of business opportunities
- General corporate purposes
Additional Information
The transaction is subject to completion of customary documentation and applicable regulatory requirements. It shall be completed in accordance with applicable laws and regulations.